University of Oxford Confidence in Concept Scheme – Round 4
Lead Research Organisation:
University of Oxford
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
- University of Oxford (Lead Research Organisation)
- Rockefeller University (Collaboration)
- University of Coimbra (Collaboration)
- UCB Pharma (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- Vaccitech Ltd (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Numares GmbH (Collaboration)
- Envigo (United Kingdom) (Collaboration)
- University of Sheffield (Collaboration)
- London School of Hygiene and Tropical Medicine (LSHTM) (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
- University of Bristol (Collaboration)
Publications
Ambrose S
(2017)
Native Desorption Electrospray Ionization Liberates Soluble and Membrane Protein Complexes from Surfaces.
in Angewandte Chemie (International ed. in English)
Bavelaar B
(2021)
Oligonucleotide-Functionalized Gold Nanoparticles for Synchronous Telomerase Inhibition, Radiosensitization, and Delivery of Theranostic Radionuclides
in Molecular Pharmaceutics
Deroy C
(2021)
Microfluidics on Standard Petri Dishes for Bioscientists.
in Small methods
Deroy C
(2022)
Assaying Macrophage Chemotaxis Using Fluid-Walled Microfluidics
in Advanced Materials Technologies
Deroy C
(2021)
Predicting flows through microfluidic circuits with fluid walls.
in Microsystems & nanoengineering
Deroy C
(2022)
Reconfigurable Microfluidic Circuits for Isolating and Retrieving Cells of Interest.
in ACS applied materials & interfaces
Fairchild P
(2019)
Immunotherapy with iPSC-derived dendritic cells brings a new perspective to an old debate: autologous versus allogeneic?
in Cell and Gene Therapy Insights
Fairchild PJ
(2016)
Beneath the sword of Damocles: regenerative medicine and the shadow of immunogenicity.
in Regenerative medicine
Frago S
(2016)
Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist.
in Proceedings of the National Academy of Sciences of the United States of America
Gill MR
(2017)
Targeted radionuclide therapy in combined-modality regimens.
in The Lancet. Oncology
| Title | Additional file 1 of Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model |
| Description | Additional file 1: Fig. S1 Weight of all animals at the 3 experimental time points. No weight differences were observed between the treatment groups at each time point on two-way ANOVA. ANOVA: analysis of variance; DTH: delayed-type hypersensitivity |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2022 |
| URL | https://springernature.figshare.com/articles/figure/Additional_file_1_of_Metabolomics_detects_clinic... |
| Title | Additional file 1 of Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model |
| Description | Additional file 1: Fig. S1 Weight of all animals at the 3 experimental time points. No weight differences were observed between the treatment groups at each time point on two-way ANOVA. ANOVA: analysis of variance; DTH: delayed-type hypersensitivity |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2022 |
| URL | https://springernature.figshare.com/articles/figure/Additional_file_1_of_Metabolomics_detects_clinic... |
| Title | Additional file 2 of Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model |
| Description | Additional file 2: Fig. S2 CSF and serum NfL concentrations in control and naïve animals. No differences in NfL concentrations were observed between the 2 groups in both (A) CSF and (B) serum on two-way ANOVA. ANOVA: analysis of variance; NfL: neurofilament-light chain |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2022 |
| URL | https://springernature.figshare.com/articles/figure/Additional_file_2_of_Metabolomics_detects_clinic... |
| Title | Additional file 2 of Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model |
| Description | Additional file 2: Fig. S2 CSF and serum NfL concentrations in control and naïve animals. No differences in NfL concentrations were observed between the 2 groups in both (A) CSF and (B) serum on two-way ANOVA. ANOVA: analysis of variance; NfL: neurofilament-light chain |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2022 |
| URL | https://springernature.figshare.com/articles/figure/Additional_file_2_of_Metabolomics_detects_clinic... |
| Title | Additional file 3 of Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model |
| Description | Additional file 3: Fig. S3 Correlation between CSF and serum NfL concentrations. (A) In all animals at all time points, (B) stratified by treatment groups at all time points, and (C) within DTH animals stratified by time points. DTH: delayed-type hypersensitivity; NfL: neurofilament-light chain; r: Pearson correlation coefficient |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2022 |
| URL | https://springernature.figshare.com/articles/figure/Additional_file_3_of_Metabolomics_detects_clinic... |
| Title | Additional file 3 of Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model |
| Description | Additional file 3: Fig. S3 Correlation between CSF and serum NfL concentrations. (A) In all animals at all time points, (B) stratified by treatment groups at all time points, and (C) within DTH animals stratified by time points. DTH: delayed-type hypersensitivity; NfL: neurofilament-light chain; r: Pearson correlation coefficient |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2022 |
| URL | https://springernature.figshare.com/articles/figure/Additional_file_3_of_Metabolomics_detects_clinic... |
| Title | Additional file 4 of Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model |
| Description | Additional file 4: Fig. S4 Comparison of clean vs. blood-contaminated CSF NMR spectra. (A) 1D-NOESY-presat spectra (chemical shift shown: 0.60 ppm - 4.20 ppm) demonstrating clean CSF (in blue) and blood-contaminated CSF (in red). This revealed aberrant NMR resonances contributed by lipoproteins and macromolecules (e.g. albumin) in blood, resulting in a broad signal with an elevated baseline (boxed region, chemical shift shown: 0.70 ppm - 1.40 ppm). (B) Zoom-in view of this boxed region showed additional resonances arising from the mobile methyl (CH3) and methylene (CH2) groups within lipoproteins, as well as from the branched chain amino acids (i.e. isoleucine, leucine, and valine). NMR: nuclear magnetic resonance; NOESY: nuclear overhauser effect spectroscopy; ppm: parts per million |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2022 |
| URL | https://springernature.figshare.com/articles/figure/Additional_file_4_of_Metabolomics_detects_clinic... |
| Title | Additional file 4 of Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model |
| Description | Additional file 4: Fig. S4 Comparison of clean vs. blood-contaminated CSF NMR spectra. (A) 1D-NOESY-presat spectra (chemical shift shown: 0.60 ppm - 4.20 ppm) demonstrating clean CSF (in blue) and blood-contaminated CSF (in red). This revealed aberrant NMR resonances contributed by lipoproteins and macromolecules (e.g. albumin) in blood, resulting in a broad signal with an elevated baseline (boxed region, chemical shift shown: 0.70 ppm - 1.40 ppm). (B) Zoom-in view of this boxed region showed additional resonances arising from the mobile methyl (CH3) and methylene (CH2) groups within lipoproteins, as well as from the branched chain amino acids (i.e. isoleucine, leucine, and valine). NMR: nuclear magnetic resonance; NOESY: nuclear overhauser effect spectroscopy; ppm: parts per million |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2022 |
| URL | https://springernature.figshare.com/articles/figure/Additional_file_4_of_Metabolomics_detects_clinic... |
| Description | Appointed to the Scientific Advisory Board of Universal Cells |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Description | Cancer Research UK Oxford Centre Development Fund |
| Amount | £15,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 02/2017 |
| Description | Cell based assays with Freestyle Microfluidics (DPhil Studentship) - Edmund Walsh Project |
| Amount | £72,000 (GBP) |
| Organisation | Iota Sciences Ltd. |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | Chang-EPA Doctoral Scholarship |
| Amount | £44,331 (GBP) |
| Organisation | Lincoln College |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Confidence in Concept |
| Amount | £42,207 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 08/2018 |
| Description | Contribution : consumables and equipment related costs for the Phd student work |
| Amount | £10,000 (GBP) |
| Organisation | OGI BIO LTD |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | Departmental PhD studentship for Rik van der Veen, Nuffield Dept. of Medicine, University of Oxford |
| Amount | £95,430 (GBP) |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2022 |
| Description | Departmental PhD studentship for Romain Guyon, Nuffield Dept. of Medicine, University of Oxford |
| Amount | £95,430 (GBP) |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2022 |
| Description | Development Fund Grant |
| Amount | £14,600 (GBP) |
| Funding ID | CRUKDF 0716-PF |
| Organisation | Cancer Research UK |
| Department | Cancer Research UK (CRUK) Oxford Centre |
| Sector | Private |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 09/2017 |
| Description | EIT Health PhD/DPhil Doctoral Transition Fellowships |
| Amount | € 42,000,000 (EUR) |
| Organisation | European Institute of Innovation and Technology (EIT) |
| Sector | Public |
| Country | Hungary |
| Start | 01/2016 |
| End | 12/2017 |
| Description | EIT Health Rare Cancer Project (KIC) Stage 1 |
| Amount | € 750,000 (EUR) |
| Organisation | European Institute of Innovation and Technology (EIT) |
| Sector | Public |
| Country | Hungary |
| Start | 03/2016 |
| End | 12/2018 |
| Description | Follow-on funding |
| Amount | £100,000 (GBP) |
| Organisation | Numares GmbH |
| Sector | Private |
| Country | Germany |
| Start | 03/2018 |
| End | 02/2020 |
| Description | Functional location of airway inflammation in eosinophilic asthma |
| Amount | £471,790 (GBP) |
| Funding ID | EP/R042160/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2018 |
| End | 12/2022 |
| Description | Guy Newton Translational Awards |
| Amount | £60,000 (GBP) |
| Funding ID | GN 05 |
| Organisation | The Guy Newton Research Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 01/2017 |
| Description | High sensitivity staging and monitoring for multiple sclerosis utilising metabolomics analysis of blood - Daniel Anthony Project |
| Amount | £240,227 (GBP) |
| Organisation | Multiple Sclerosis Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | John Fell Fund OUP Research Fund. Measuring inhomogeneity of the lung as a means of endotyping lung disease |
| Amount | £38,000 (GBP) |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 03/2022 |
| Description | Lab282 |
| Amount | £231,405 (GBP) |
| Funding ID | OUI 15169 |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 08/2018 |
| Description | Laser gas analyser sub-theme of Oxford BRC theme in Respiratory Medicine - Peter Robbins Project |
| Amount | £450,000 (GBP) |
| Organisation | Oxford University Hospitals NHS Foundation Trust |
| Department | NIHR Oxford Biomedical Research Centre |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Lord Leonard and Lady Estelle Wolfson Foundation Translation Award - Sunetra Gupta Project |
| Amount | £50,000 (GBP) |
| Organisation | The Royal Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | MPLS Translation Award - Sunetra Gupta Project |
| Amount | £71,729 (GBP) |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | MRC CiC Award Oxford |
| Amount | £1,000,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2017 |
| Description | MRC Confidence in Concept Round 4 |
| Amount | £33,835 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 08/2018 |
| Description | Merck Grant for Multiple Sclerosis Innovation (GMSI) - Daniel Anthony Project |
| Amount | € 366,339 (EUR) |
| Organisation | Merck |
| Sector | Private |
| Country | Germany |
| Start | |
| Description | Project Grant |
| Amount | £9,700 (GBP) |
| Funding ID | OHSRC 1231 |
| Organisation | Oxford Radcliffe Hospitals Charitable Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Proof of Concept Award - Sunetra Gupta Project |
| Amount | € 149,307 (EUR) |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | |
| Description | RIO Clinical Trial: Set up award |
| Amount | £90,267 (GBP) |
| Organisation | Bill and Melinda Gates Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 09/2018 |
| End | 09/2019 |
| Description | Research project grant |
| Amount | £37,000 (GBP) |
| Funding ID | M638 |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 02/2019 |
| Description | Single administration of prime-boost malaria vaccine enabled by engineering advancements in precise vaccine encapsulation methods - Anita Milicic Project |
| Amount | £48,000 (GBP) |
| Organisation | Liverpool School of Tropical Medicine |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | The Idealised Lung Clearance Index: tuning in to the silent years of cystic fibrosis |
| Amount | £461,345 (GBP) |
| Funding ID | EP/T001186/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 01/2023 |
| Description | The PITCH Study Arm |
| Amount | £199,999 (GBP) |
| Organisation | amfAR, The Foundation for AIDS Research |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 09/2018 |
| End | 09/2021 |
| Description | The idealised LCI (i-LCI): tuning in on the silent years of paediatric CF |
| Amount | £98,595 (GBP) |
| Funding ID | VIA068 |
| Organisation | Cystic Fibrosis Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 12/2022 |
| Description | UCSF |
| Amount | £66,497 (GBP) |
| Organisation | Oxford Innovation Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2018 |
| Description | Using Genome Variation to Sort Extremely Rare Cell Populations for Clinical Application |
| Amount | £59,529 (GBP) |
| Organisation | Medical and Life Sciences Translational Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 03/2020 |
| Title | Microfluidic sorting |
| Description | Assay developed to microfluidic droplets to enrich and sort very rare cell populations |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | Working with Physical Chemistry this method is being optimised for clinical application. Patents currently being applied for |
| Title | Refining sample handling and collection procedures - Sibson project |
| Description | By fostering new collaborations and having dedicated research assistant time in the clinic, we have been able to refine our sample handling and collection procedures with direct clinical feedback. This has included dedicated pro-formas and optimised handling and processing procedures which has resulted in higher recruitment rates and will be useful for undertaking further similar studies. |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | Optimised handling and processing procedures which has resulted in higher recruitment rates and will be useful for undertaking further similar studies. |
| Title | Sequencing bioinformatics |
| Description | Application of sureselect enrichment to rare DNA integrants in clinical samples |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | The SOP for this method will be made available following publication This technique allows next gen sequencing of rare proviral HIV sequences - currently not possible consistently using present methodology Manuscript in preparation |
| Description | Assay development to facilitate vaccine progression for Shingles |
| Organisation | London School of Hygiene and Tropical Medicine (LSHTM) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Transfer of assay and SOP to other laboratories. We will collaborate with Prof Helen Fletcher, based at the London School of Hygiene & Tropical Medicine, to transfer the newly developed assay and compare the outputs for reproducibility, accuracy and robustness. |
| Collaborator Contribution | To facilitate the progress to market of new VZV-specific vaccines, we propose to develop a standardized peptide-based ELISPOT assay, which will be specific, reproducible, reliable and easily transferrable. Works carried out in Prof. Fletcher's laboratory will aid in the assessment of the ease to which the assay can be transferred. |
| Impact | Collaboration in place; results pending. |
| Start Year | 2017 |
| Description | Collaboration/Partner |
| Organisation | Vaccitech Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The commercial partner for this application are interested in further assessing the viability of the end product(s) that have been borne out of this research and other funded work in the same area. |
| Collaborator Contribution | Ongoing work in the same field. |
| Impact | Ongoing. |
| Start Year | 2017 |
| Description | Department of Chemistry, University of Bristol |
| Organisation | University of Bristol |
| Department | School of Chemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration with Professor Matthew Crump on the structure and function of domain 11 of IGF2R. Sharing reagents and experiments. |
| Collaborator Contribution | Development of FRET based assays for free IGF2 using covalent linkage of IGF2 and domain 11, validated with NMR. |
| Impact | Multiple co-authored publications. Patent application co-IP. |
| Start Year | 2006 |
| Description | Department of Chemistry, University of Sheffield |
| Organisation | University of Sheffield |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Research collaboration to develop new chemical class of radiosensitizer for drug delivery. Synthetic source of chemical(s) for MRC CiC award. |
| Collaborator Contribution | Partners bring chemical synthesis expertise. |
| Impact | Multi-disciplinary (Chemistry) to add to Biological/Medical Science. |
| Start Year | 2016 |
| Description | Dept Of Physical Chemistry, University of Oxford |
| Organisation | University of Oxford |
| Department | Physical and Theoretical Chemistry Laboratory |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Research collaboration to develop microfluidic diagnostic platforms. Awarded MRC CiC grant and UCSF award. |
| Collaborator Contribution | Partners bring expertise in microfluidics |
| Impact | CIC Funding UCSF funding Patents pending |
| Start Year | 2016 |
| Description | Diagnosis of brain tumours by biofluid metabolomics |
| Organisation | University of Oxford |
| Department | Department of Oncology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have established a collaboration with clinical colleagues in the Department of Oncology to obtain patient samples for metabolomics analysis. Our contribution is to undertake all sample processing and analysis, together with computational modelling and data interpretation. |
| Collaborator Contribution | Our collaborators have facilitated sample collection from patients at their regular clinics. |
| Impact | STEM for Britain Parliamentary Exhibition: Silver Medal Winner (post-doc on project). Wellcome Institutional Strategic Support Fund award (post-doc on project co-I): Developing new approaches to early disease detection using a primary care cohort with vague non-specific symptoms; £15k |
| Start Year | 2016 |
| Description | GSK Therapeutics - Robbins Project - How are novel, non-invasive measures of lung heterogeneity affected during treatment of airways disease with GSK therapeutics? |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Assessment of non-invasive measures of lung heterogeneity following treatment of airways disease with GSK therapeutics. |
| Collaborator Contribution | Assessment of non-invasive measures of lung heterogeneity following treatment of airways disease with GSK therapeutics. |
| Impact | N/A |
| Start Year | 2018 |
| Description | Imaging of IGF2-TRAP |
| Organisation | University of Coimbra |
| Country | Portugal |
| Sector | Academic/University |
| PI Contribution | Provided proteins for DOTA labelling |
| Collaborator Contribution | Labelling and imaging of IGF2-TRAP using PET CT |
| Impact | None yet |
| Start Year | 2017 |
| Description | Imperial and King's College |
| Organisation | Imperial College London |
| Department | Department of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contribute expertise, patient recruitment, strategy and laboratory assays to this NIHR collaboration |
| Collaborator Contribution | Contribute expertise, patient recruitment, strategy and laboratory assays to this NIHR collaboration. Part of the evolution of the CHERUB network |
| Impact | Multiple publications (listed), new collaborations (eg Rockefeller - listed) and new funding (detailed) |
| Start Year | 2014 |
| Description | Imperial and King's College |
| Organisation | King's College London |
| Department | Division of Immunology, Infection & Inflammatory Diseases (DIIID) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contribute expertise, patient recruitment, strategy and laboratory assays to this NIHR collaboration |
| Collaborator Contribution | Contribute expertise, patient recruitment, strategy and laboratory assays to this NIHR collaboration. Part of the evolution of the CHERUB network |
| Impact | Multiple publications (listed), new collaborations (eg Rockefeller - listed) and new funding (detailed) |
| Start Year | 2014 |
| Description | Monoclonal antibody production against vaccine antigen |
| Organisation | Envigo |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We have secured funding for this collaboration. We developed and supplied the protein vaccine antigen and will test functionality of mAb generated by different clones selected by our collaborator. |
| Collaborator Contribution | Antibodies specific to our novel vaccine antigen do not exist leading to a reliance on non-specific fusion tags. In collaboration with us, our partner will supply this valuable new resource which will enable accurate data interpretation of the effects of new vaccine candidates. |
| Impact | Collaboration in place; results pending. |
| Start Year | 2017 |
| Description | Partnership with Numares AG - Daniel Anthony Project |
| Organisation | Numares GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | Provision of IP, ongoing development of research |
| Collaborator Contribution | Take a license from existing IP, pay ongoing patent costs and fund an extension of the project to translate methods into a clinical setting |
| Impact | None yet |
| Start Year | 2016 |
| Description | RIO Clinical Trial |
| Organisation | Imperial College London |
| Department | Faculty of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This is a new collaborative project funded by the Bill and Melinda Gates Foundation. Funding is pending but the grant is worth $6.5 million and should be confirmed by the end of March 2019. This is a collaboration between Oxford, Imperial and Rockefeller to run a clinical trial of neutralising antibody therapy to treat HIV in the UK. |
| Collaborator Contribution | Rockefeller provides neutralising antibodies for the trial, Imperial provides clinical trial expertise and Oxford provides laboratory assays |
| Impact | Set-up grant from BMGF Knowledge exchange for assays |
| Start Year | 2018 |
| Description | RIO Clinical Trial |
| Organisation | Rockefeller University |
| Department | Laboratory of Virology and Infectious Disease |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | This is a new collaborative project funded by the Bill and Melinda Gates Foundation. Funding is pending but the grant is worth $6.5 million and should be confirmed by the end of March 2019. This is a collaboration between Oxford, Imperial and Rockefeller to run a clinical trial of neutralising antibody therapy to treat HIV in the UK. |
| Collaborator Contribution | Rockefeller provides neutralising antibodies for the trial, Imperial provides clinical trial expertise and Oxford provides laboratory assays |
| Impact | Set-up grant from BMGF Knowledge exchange for assays |
| Start Year | 2018 |
| Description | RIO Trial - Set Up award |
| Organisation | Rockefeller University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Sequence potential participants for the trial Develop the protocol |
| Collaborator Contribution | Sponsorship Protocol development Knowledge exchange |
| Impact | Knowledge exchange Assay development Development of full grant award |
| Start Year | 2018 |
| Description | UCB Pharma |
| Organisation | UCB Pharma |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Provided constructs for IGF2-TRAP mutants. |
| Collaborator Contribution | Expressed IGF2-TRAP proteins, perfumed formulation screens and stability studies. Re-egineered the FC linker region to avoid proteolytic degradation. |
| Impact | None as yet |
| Start Year | 2016 |
| Title | IMMUNOGENIC COMPOSITION |
| Description | The present invention relates to an immunogenic composition comprising two or more polypeptides. The invention also provides nucleic acid molecules and vectors encoding the polypeptides, and methods of using the compositions, nucleic acid molecules and vectors for the prevention or treatment of influenza. |
| IP Reference | WO2018037246 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | Yes |
| Impact | An opinion to take out a licencing agreement has been agreed with Blue Water Vaccines. A US/UK-based startup assembled to commercialise the flu vaccine we're developing. Additional research funding in the form of a £460k research agreement has been agreed with the university due to the licencing agreement. This will pay for Dr Thompson's salary. In addition to this, a 14.5 million USD agreement regarding the development of the vaccine has been agreed. Part of this money will be spent on clinical |
| Title | INDUCED PLURIPOTENT STEM CELLS PRODUCED FROM DENDRITIC CELLS |
| Description | The invention relates to induced pluripotent stem cells (iPSCs) produced from source dendritic cells (DCs). The invention also relates to synthetic DCs re-differentiated the iPSCs and which display a definitive adult phenotype rather than a primitive fetal/neonatal phenotype. The invention also relates to methods for making and methods of using the iPSCs and DCs of the invention. |
| IP Reference | WO2017129981 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | Commercial In Confidence |
| Impact | Establishing spin-out |
| Title | INSULIN-LIKE GROWTH FACTOR 2 (IGF2) BINDING AGENTS |
| Description | This invention relates to mutant polypeptides comprising the IGF2 binding domain of the Insulin-like Growth Factor 2 Receptor (IGF2R) with residue P1597 is substituted for a different residue, for example H or K. Other residues which may be mutated include S1543, E1544, K1545, G1546, L1547, Q1569, S1602, G1603 and/or K1631. These IGF2 binding domains display dramatically increased binding affinity for IGF2 compared to both the wild-type and previously identified mutants and may be useful for example in cancer therapy. |
| IP Reference | WO2017029148 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | Commercial In Confidence |
| Impact | Development ongoing |
| Title | METHODS AND APPARATUS FOR ADDING OR REMOVING MATERIAL FROM A MICROFLUIDIC ARRANGEMENT |
| Description | Methods and apparatus for adding or removing material from a microfluidic arrangement are disclosed. The microfluidic arrangement may comprise a plurality of bodies of a first liquid held in shape by surface tension on a substrate. A second liquid covers the bodies of first liquid. A port is scanned along a scanning path. Material is added via the port to plural bodies of the first liquid without changing their footprints during a segment of the scanning path. Alternatively, material is removed via the port from plural bodies of the first liquid without changing their footprints during a segment of the scanning path. The port is moved through a range of positions exclusively at a constant distance from the substrate during each segment of the scanning path. |
| IP Reference | EP3482828 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | Yes |
| Impact | iotaSciences Ltd is exploiting this technology |
| Title | METHODS AND APPARATUS FOR CONTROLLING FLOW IN A MICROFLUIDIC ARRANGEMENT, AND A MICROFLUIDIC ARRANGEMENT |
| Description | Methods and apparatus for controlling flow in a microfluidic arrangement are disclosed. In one arrangement, a microfluidic arrangement comprises a first liquid held predominantly by surface tension in a shape defining a microfluidic pattern on a surface of a substrate. The microfluidic pattern comprises at least an elongate conduit and a first reservoir. A second liquid is in direct contact with the first liquid and covers the microfluidic pattern. A flow of liquid is driven through the elongate conduit into the first reservoir. The microfluidic pattern and the depth and density of the second liquid are such that the first reservoir grows in volume during the flow of liquid into the first reservoir, without either of the size and shape of an area of contact between the first reservoir and the substrate changing, until an upper portion of the first reservoir detaches from a lower portion of the first reservoir due to buoyancy and rises upwards through the second liquid, thereby allowing the first reservoir to continue to receive liquid from the flow of liquid without any change in the size and shape of the area of contact between the first reservoir and the substrate. |
| IP Reference | US2019168212 |
| Protection | Patent granted |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | Other patents in process of filing over the coming months |
| Title | METHODS AND APPARATUS FOR DRIVING FLOW IN A MICROFLUIDIC ARRANGEMENT |
| Description | Methods and apparatus for driving flow in a microfluidic arrangement are provided. In one disclosed arrangement, the microfluidic arrangement comprises a first liquid held predominantly by surface tension in a shape defining a microfluidic pattern on a surface of a substrate. The microfluidic pattern comprises at least an elongate conduit and a first reservoir. The area of contact between the substrate and a portion of the first liquid that forms the elongate conduit defines a conduit footprint. The area of contact between the substrate and a portion of the first liquid that forms the first reservoir defines a first reservoir footprint. The size and shape of each of the conduit footprint and the first reservoir footprint are such that a maximum Laplace pressure supportable by the first liquid in the elongate conduit without any change in the conduit footprint is higher than a maximum Laplace pressure supportable by the first liquid in the first reservoir without any change in the first reservoir footprint. A delivery member having an internal lumen leading to a distal opening through which liquid can be delivered is provided. Liquid is pumped into the microfluidic pattern through the distal opening while the distal opening is held in a delivery position. The delivery position is such that the liquid enters the microfluidic pattern via the elongate conduit and drives a flow of liquid into the first reservoir. |
| IP Reference | US2020129977 |
| Protection | Patent granted |
| Year Protection Granted | 2020 |
| Licensed | No |
| Impact | Further patent applications will be submitted in the coming year |
| Title | Method and apparatus for quantifying lung function |
| Description | A method and apparatus for non-invasive assessment of lung inhomogeneity by accurate high temporal resolution measurement of respiratory gas flows at the mouth during steady state breathing and inert gas wash-in or wash-out and using these measurements to fit a mathematical model of the inhomogeneous lung. The model of the lung is based on modelling the lung as plural alveolar compartments each having an identical volume at functional residual capacity, but varying in its fractional share of total lung compliance, total pulmonary vascular conductance and total anatomical deadspace. A bivariate log-normal distribution of the lung compliance and pulmonary vascular conductance is used, together with a normal distribution of deadspace fraction. The model is fitted to the measurements using non-linear regression and the distribution of ventilation: perfusion ratios, lung compliance: volume ratios, lung vascular conductance: volume ratios and lung deadspace: volume ratios obtained from the fitted model are indicative of the airway condition and thus lung function of the subject. |
| IP Reference | US 16/328,773 |
| Protection | Patent granted |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | A method and apparatus for non-invasive assessment of lung inhomogeneity by accurate high temporal resolution measurement of respiratory gas flows at the mouth during steady state breathing and inert gas wash-in or wash-out and using these measurements to fit a mathematical model of the inhomogeneous lung. The model of the lung is based on modelling the lung as plural alveolar compartments each having an identical volume at functional residual capacity, but varying in its fractional share of total lung compliance, total pulmonary vascular conductance and total anatomical deadspace. A bivariate log-normal distribution of the lung compliance and pulmonary vascular conductance is used, together with a normal distribution of deadspace fraction. The model is fitted to the measurements using non-linear regression and the distribution of ventilation: perfusion ratios, lung compliance: volume ratios, lung vascular conductance: volume ratios and lung deadspace: volume ratios obtained from the fitted model are indicative of the airway condition and thus lung function of the subject. |
| Title | Methods and apparatus for manufacturing a microfluidic arrangement, and a microfluidic arrangement |
| Description | Development of a method for making an analogue of a microplate |
| IP Reference | GB1720771.3 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | Yes |
| Impact | This IP is being exploited by iotaSciences LTD |
| Title | Methods and apparatus for manufacturing a microfluidic arrangement, and a microfluidic arrangement' |
| Description | the development of methods to make microfluidic circuits involving forcing an immiscible liquid through an aqueous phase on to a substrate. |
| IP Reference | GB1802819.1 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | Yes |
| Impact | This technology is being exploited by iotaSciences LTD |
| Title | Validated Assay |
| Description | Validated Assay for primary endpoint readout for use in clinical trials |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2017 |
| Development Status | Under active development/distribution |
| Impact | n/a |
| Company Name | BLUE WATER VACCINES INC. |
| Description | A company developing a universal flu vaccine based on technology developed at the University of Oxford |
| Year Established | 2019 |
| Impact | Vaccine development & clinical trials |
| Website | https://www.bluewatervaccines.com/ |
| Company Name | iotaSciences |
| Description | iotaSciences develops technology called Freestyle Fluidics that shapes fluids and attaches them to chips, with applications in microbiology such as in valves, connectors, and pumps. |
| Year Established | 2016 |
| Impact | This company is commercializing a novel way of performing microfluidics |
| Website | http://www.iotasciences.com |
| Description | Abingdon Science Festival |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | A plenary presentation as part of a three day festival of science. My presentation was entitled 'Tapping the fountain of youth: Stem cells and the promise of regenerative medicine'. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.atomfestival.org.uk/events/stem-cells/ |
| Description | All Saints Church, Marlow |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Invited to give a presentation and lead a discussion on the ethics of stem cell research. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Annual Rayleigh Lecture (Harrow School) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | I was invited to deliver the 2018 Rayleigh Lecture at Harrow School on the ethics of stem cell research. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Article 29 |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | An article published in the Young Scientist Journal reviewing the lecture I gave as part of the ATOM Science Festival. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Article 30 |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A commentary discussed the publication of one of our papers and its implications for immunotherapy. |
| Year(s) Of Engagement Activity | 2017 |
| Description | CHELSEA FLOWER SHOW HIV STIGMA GARDEN |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Garden presented at RHS Chelsea 2018. Themed on HIV Stigma. Won Silver Guilt Award. Huge national and international media attention. Prime time BBC1 TV report on the garden as well as national and international TV and Radio coverage. Handed out 10,000 leaflets on site. Estimated audience greater than 3 million |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.medsci.ox.ac.uk/cherub-hiv-garden |
| Description | Cafe Scientifique (Marlow) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | I was invited to lead a workshop for students and members of the general public on the promise of regenerative medicine. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Cell and Gene Therapy Congress |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Plenary speaker at an international congress. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Drug Target Review |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Article on using native mass spectrometry to inform drug discovery. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.drugtargetreview.com/article/23594/drug-target-review-issue-2-2017/ |
| Description | EIT Health Summer School Rare Cancer |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | EIT health summer in Rare cancer at two centres Budapest and Oxford. Innovation by design and educational summer school |
| Year(s) Of Engagement Activity | 2016 |
| Description | EIT health Rotterdam Meeting: Rare Cancer Project presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Presenation of an EIT health project on Rare Cancer to the kick-off meeting in Rotterdam |
| Year(s) Of Engagement Activity | 2016 |
| Description | European Association of Nuclear Medicine (EANM) Meeting and Congress, Vienna |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Round Table discussion at WARMTH (World Association of Radiopharmaceutical and Molecular Therapy) Congress (Professor Katherine Vallis). This resulted in establishment of relations with Theranostics Australia, followed by formal visit of CEO and Chief Scientific Officer to Oxford to solidify and develop research overlap and potential future collaboration. |
| Year(s) Of Engagement Activity | 2017 |
| Description | GlaxoSmithKline |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | An invitation to contribute to a seminar series. |
| Year(s) Of Engagement Activity | 2016 |
| Description | J Larkin_Presentation about research and discussion about cancer at a local school event (Oxford, 2014) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Audience: Local members of the public, school age (between 6 and 9 years old). Presentation about being a scientist and what I do at work as well as cancer and the treatments. |
| Year(s) Of Engagement Activity | 2014 |
| Description | Keynote speaker at the Faraday Institute Summer School, Cambridge |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Invited lecture on the 'Ethical challenges of stem cells and reproductive technologies'. The lecture elicited significant debate among attendees. As a result of this activity, I was invited to deliver a series of three lectrues on similar subjects across India. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Mercedes Family Day |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Manned a stall at the Mercedes family day for CRUK, explaining aspects of cancer research within the Institute. Lots of people participated and were very engaged and interested in the research being done. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Norway: Oslo and Bergen lectures" Challenges of Rare Cancers" and 'Evolution of an IGF2-TRAP' |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Two lectures given in Bergen and video linked to Oslo Radium Hospital and Institute of Cancer Research |
| Year(s) Of Engagement Activity | 2016 |
| Description | Precision Medicine and Digital Health Technology Showcase |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Poster presentation (MG): Organised by OUI to promote IP and academics where companies and investors plus other ancillary functions attend. Approach and link with Frontier IP made. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Production of video on our technology for measurement in critical care and respiratory medicine |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Promote our technology to potential commercial funders. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://oxfordbrc.nihr.ac.uk/research-themes-overview/respiratory/videos-respiratory/ |
| Description | Publicity (press and radio) around publication of project results - Sunetra Gupta Project |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Publicity of the paper funded through the CiC grant; covered by 17 news outlets in several foreign languages. Also a radio interview on local BBC Radio Oxford |
| Year(s) Of Engagement Activity | 2018 |
| Description | Scientific Advisory Board for Hungarian Academy of Sciences: Hungary Institute of Molecular Medicine |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Presentation on Oxford and Thames Valley Molecular Medicine Developments. Workshop and closed advisory board on the Development of a Hungarian Institute of Molecular Medicine. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Workshop on Genetic Modification (Dunottar School) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Lead a workshop and debate about the use and importance of genetic modification. |
| Year(s) Of Engagement Activity | 2017 |